Universtitätsklinikum Essen AöR
Welcome,         Profile    Billing    Logout  
 5 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reinhardt, Dirk
NCT04793919 / 2017-002383-40: Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Recruiting
2
89
Europe, RoW
Mylotarg, GO, Arsenic Trioxide, ATO, All-trans retinoic acid, ATRA
Associazione Italiana Ematologia Oncologia Pediatrica, AIEOP
Acute Promyelocytic Leukemia
10/25
10/27
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
PerVision, NCT06094101 / 2022-002793-91: Personalized Vaccination in Fusion+ Sarcoma Patients

Recruiting
1/2
30
Europe
Peptide vaccine IPX
University Hospital Tuebingen, Deutsches Konsortium fürTranslationale Krebsforschung (DKTK), Cooperative Ewing Sarkom Studiengruppe, Cooperative Weichteilsarkom Study Group
Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma
06/27
09/27
NCT04238819: A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Active, not recruiting
1/2
117
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide, Dinutuximab, GM-CSF
Eli Lilly and Company
Relapsed Solid Tumor, Refractory Solid Tumor
03/24
04/25
HEM-iSMART D, NCT05658640: HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies

Recruiting
1/2
26
Europe, RoW
Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy
Princess Maxima Center for Pediatric Oncology, Innovative Therapies For Children with Cancer Consortium, IBFM, Fight Kids Cancer
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
04/29
04/29
Holle-Lee, Dagny
CHERUB01, NCT04970355: Efficacy of Erenumab in Chronic Cluster Headache

Completed
2
101
Europe
Erenumab, AMG 334, Placebo
Charite University, Berlin, Germany
Cluster Headache, Trigeminal Autonomic Cephalalgias, Headache Disorders, Primary, Brain Disease
09/23
09/23
PAREMA1, NCT05546385: PArtial REbreathing for Migraine with Aura 1

Terminated
N/A
142
Europe, US
Partial Rebreathing Device, Sham breathing device
Rehaler, Qmed Consulting A/S
Migraine with Aura
10/24
10/24
NCT05843721: Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects with Chronic Migraine

Recruiting
N/A
200
Europe, RoW
KOS (Intranasal kinetic oscillation stimulation)
Chordate Medical
Chronic Migraine
03/25
03/26
Barraclough, Allison
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
TOP-FLOR, NCT05788081: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Recruiting
2
40
RoW
golcadomide, BMS-986369, CC-99282, Nivolumab 10 MG/ML, Opdivo, Rituximab, Mabthera
Olivia Newton-John Cancer Research Institute, Austin Health, Grampians Health, Fiona Stanley Hospital, Eastern Health, Barwon Health, Bristol-Myers Squibb
Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV
01/27
06/27

Download Options